D. Beauvais, B. Burbach, and A. Rapraeger, integrin activity in human mammary carcinoma cells, The Journal of Cell Biology, vol.162, issue.1, pp.171-181, 2004.
DOI : 10.1046/j.1365-2141.1996.d01-1811.x

M. Bernfield, M. Gotte, P. Park, O. Reizes, M. Fitzgerald et al., Functions of Cell Surface Heparan Sulfate Proteoglycans, Annual Review of Biochemistry, vol.68, issue.1, pp.729-777, 1999.
DOI : 10.1146/annurev.biochem.68.1.729

L. Jakobsson, J. Kreuger, K. Holmborn, L. Lundin, I. Eriksson et al., Heparan Sulfate in trans Potentiates VEGFR-Mediated Angiogenesis, Developmental Cell, vol.10, issue.5, pp.625-634, 2006.
DOI : 10.1016/j.devcel.2006.03.009

M. Solursh, R. Reiter, K. Jensen, M. Kato, and M. Bernfield, Transient expression of a cell surface heparan sulfate proteoglycan (syndecan) during limb development, Developmental Biology, vol.140, issue.1, pp.83-92, 1990.
DOI : 10.1016/0012-1606(90)90055-N

N. Ilan, M. Elkin, and I. Vlodavsky, Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis, The International Journal of Biochemistry & Cell Biology, vol.38, issue.12, pp.2018-2039, 2006.
DOI : 10.1016/j.biocel.2006.06.004

P. Derksen, R. Keehnen, L. Evers, M. Van-oers, M. Spaargaren et al., Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma, Blood, vol.99, issue.4, pp.1405-1410, 2002.
DOI : 10.1182/blood.V99.4.1405

G. Yip, M. Smollich, and M. Gotte, Therapeutic value of glycosaminoglycans in cancer, Molecular Cancer Therapeutics, vol.5, issue.9, pp.2139-2148, 2006.
DOI : 10.1158/1535-7163.MCT-06-0082

F. Baba, K. Swartz, R. Van-buren, J. Eickhoff, Y. Zhang et al., Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype, Breast Cancer Research and Treatment, vol.1, issue.Pt 6, pp.91-99, 2006.
DOI : 10.1007/s10549-005-9135-2

E. Rakha, M. Sayed, A. Green, A. Lee, J. Robertson et al., Prognostic markers in triple-negative breast cancer, Cancer, vol.91, issue.1, pp.25-32, 2007.
DOI : 10.1002/cncr.22381

B. Haffty, Q. Yang, M. Reiss, T. Kearney, S. Higgins et al., Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer, Journal of Clinical Oncology, vol.24, issue.36, pp.245652-5657, 2006.
DOI : 10.1200/JCO.2006.06.5664

C. Oakman, G. Viale, and D. Leo, Management of triple negative breast cancer, The Breast, vol.19, issue.5, pp.312-333
DOI : 10.1016/j.breast.2010.03.026

W. Irvin, . Jr, and L. Carey, What is triple-negative breast cancer?, European Journal of Cancer, vol.44, issue.18, pp.2799-2805, 2008.
DOI : 10.1016/j.ejca.2008.09.034

J. Wijdenes, W. Vooijs, C. Clement, J. Post, F. Morard et al., A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, British Journal of Haematology, vol.94, issue.2, pp.318-323, 1996.
DOI : 10.1046/j.1365-2141.1996.d01-1811.x

O. Couturier, A. Faivre-chauvet, I. Filippovich, P. Thedrez, C. Sai-maurel et al., Chérel M: Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma, Clin Cancer Res, vol.5, pp.3165-3170, 1999.

S. Supiot, A. Faivre-chauvet, O. Couturier, M. Heymann, N. Robillard et al., Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.335, issue.S4, 2002.
DOI : 10.1002/cncr.10286

S. Denardo, O. Grady, L. Richman, C. Denardo, and G. , Overview of Radioimmunotherapy in Advanced Breast Cancer Using I-131 Chimeric L6
DOI : 10.1007/978-1-4615-2443-4_19

D. Schrier, S. Stemmer, T. Johnson, R. Kasliwal, J. Lear et al., High-dose 90Y Mxdiethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial, Cancer Res, issue.23, pp.555921-5924, 1995.

T. Behr, R. Sharkey, M. Juweid, R. Dunn, R. Vagg et al., Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG, J Nucl Med, issue.6, pp.38858-870, 1997.

T. Mulligan, J. Carrasquillo, Y. Chung, D. Milenic, J. Schlom et al., Shauffnessy J: Phase I study of intravenous Lulabeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma, Clin Cancer Res, vol.1, issue.12, pp.1447-1454, 1995.

C. Oliveras-ferraros, A. Vazquez-martin, E. Lopez-bonet, B. Martin-castillo, D. Barco et al., Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer, Int J Oncol, issue.6, pp.331165-1176, 2008.

K. Bernardeau, S. Gouard, G. David, A. Ruellan, A. Devys et al., Assessment of CD8 involvement in T???cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody, European Journal of Immunology, vol.154, issue.10, pp.352864-2875, 2005.
DOI : 10.1002/eji.200526307

P. Fraker, J. Speck, and . Jr, Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, Biochemical and Biophysical Research Communications, vol.80, issue.4, pp.849-857, 1978.
DOI : 10.1016/0006-291X(78)91322-0

T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, P. Bunn et al., Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, Journal of Immunological Methods, vol.72, issue.1, pp.77-89, 1984.
DOI : 10.1016/0022-1759(84)90435-6

B. Burbach, A. Friedl, C. Mundhenke, and A. Rapraeger, Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells, Matrix Biology, vol.22, issue.2, pp.163-77, 2003.
DOI : 10.1016/S0945-053X(03)00009-X

L. Shih, H. Xuan, R. Aninipot, R. Stein, and D. Goldenberg, In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer, Cancer Res, issue.23, pp.555857-5863, 1995.

S. Govindan, R. Stein, Z. Qu, S. Chen, P. Andrews et al., Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel, Breast Cancer Research and Treatment, vol.94, issue.2, pp.173-182, 2004.
DOI : 10.1023/B:BREA.0000018417.02580.ef

M. Gotte, C. Kersting, I. Radke, L. Kiesel, and P. Wulfing, An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ, Breast Cancer Research, vol.9, issue.1, p.8, 2007.
DOI : 10.1186/bcr1641

K. Clarke, F. Lee, M. Brechbiel, F. Smyth, L. Old et al., Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy, Clin Cancer Res, vol.6, issue.9, pp.3621-3628, 2000.

J. Peterson, E. Blank, and R. Ceriani, Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas, Cancer Res, vol.57, issue.6, pp.1103-1108, 1997.

T. Behr, S. Memtsoudis, R. Sharkey, R. Blumenthal, R. Dunn et al., Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy, Int J Cancer, issue.5, pp.77787-795, 1998.

T. Behr, E. Wulst, S. Radetzky, R. Blumenthal, R. Dunn et al., Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type, Cancer Res, issue.23, pp.575309-5319, 1997.

T. Behr, G. Sgouros, V. Vougiokas, S. Memtsoudis, S. Gratz et al., Therapeutic efficacy and doselimiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model, Int J Cancer, issue.5, pp.76738-76786, 1998.

T. Liersch, J. Meller, M. Bittrich, B. Kulle, H. Becker et al., Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group, Annals of Surgical Oncology, vol.139, issue.Suppl 2, pp.2577-2590, 2007.
DOI : 10.1245/s10434-006-9328-x

M. Leahy and J. Turner, Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients, Blood, vol.117, issue.1, pp.45-52, 2011.
DOI : 10.1182/blood-2010-02-269753

M. Leahy, J. Seymour, R. Hicks, and J. Turner, Multicenter Phase II Clinical Study of Iodine-131???Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.24, issue.27, pp.244418-4425, 2006.
DOI : 10.1200/JCO.2005.05.3470

H. Jacene, R. Filice, W. Kasecamp, and R. Wahl, Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice, Journal of Nuclear Medicine, vol.48, issue.11, pp.481767-1776, 2007.
DOI : 10.2967/jnumed.107.043489

L. Wilsie, A. Gonzales, and R. Orlando, Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway, Lipids in Health and Disease, vol.5, issue.1, p.23, 2006.
DOI : 10.1186/1476-511X-5-23

I. Fuki, M. Meyer, and K. Williams, Transmembrane and cytoplasmic domains of syndecan mediate a multi-step endocytic pathway involving detergent-insoluble membrane rafts, Biochem J, pp.351607-351619, 2000.

M. Leivonen, J. Lundin, S. Nordling, V. Boguslawski, K. Haglund et al., Prognostic Value of Syndecan-1 Expression in Breast Cancer, Oncology, vol.67, issue.1, pp.11-18, 2004.
DOI : 10.1159/000080280

M. Barbareschi, P. Maisonneuve, D. Aldovini, M. Cangi, L. Pecciarini et al., High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis, Cancer, vol.17, issue.3, pp.98474-83, 2003.
DOI : 10.1002/cncr.11515

A. Gopal, O. Press, S. Wilbur, D. Maloney, and J. Pagel, Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab, Blood, vol.112, issue.3, pp.830-835, 2008.
DOI : 10.1182/blood-2008-01-132142

T. Maeda, J. Desouky, and A. Friedl, Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis, Oncogene, vol.100, issue.9, pp.1408-1412, 2006.
DOI : 10.1038/sj.onc.1209168

D. Mennerich, A. Vogel, I. Klaman, E. Dahl, R. Lichtner et al., Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours, European Journal of Cancer, vol.40, issue.9, pp.401373-1382, 2004.
DOI : 10.1016/j.ejca.2004.01.038

. Rousseau, Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors, EJNMMI Research, vol.1, issue.1, p.20, 2011.
DOI : 10.1016/j.ejca.2004.01.038

URL : https://hal.archives-ouvertes.fr/inserm-00626326